Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
ELOS's Cash to Debt is ranked higher than
88% of the 479 Companies
in the Global Medical Devices industry.

( Industry Median: 2.00 vs. ELOS: No Debt )
ELOS' s 10-Year Cash to Debt Range
Min: 15.11   Max: No Debt
Current: No Debt

Equity to Asset 0.74
ELOS's Equity to Asset is ranked higher than
81% of the 449 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. ELOS: 0.74 )
ELOS' s 10-Year Equity to Asset Range
Min: 0.5   Max: 0.86
Current: 0.74

0.5
0.86
F-Score: 6
Z-Score: 4.83
M-Score: -2.87
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) -0.87
ELOS's Operating margin (%) is ranked higher than
65% of the 463 Companies
in the Global Medical Devices industry.

( Industry Median: 6.11 vs. ELOS: -0.87 )
ELOS' s 10-Year Operating margin (%) Range
Min: -249.56   Max: 44.31
Current: -0.87

-249.56
44.31
Net-margin (%) -2.03
ELOS's Net-margin (%) is ranked higher than
64% of the 463 Companies
in the Global Medical Devices industry.

( Industry Median: 4.39 vs. ELOS: -2.03 )
ELOS' s 10-Year Net-margin (%) Range
Min: -243.89   Max: 47.2
Current: -2.03

-243.89
47.2
ROE (%) -2.25
ELOS's ROE (%) is ranked higher than
64% of the 448 Companies
in the Global Medical Devices industry.

( Industry Median: 5.76 vs. ELOS: -2.25 )
ELOS' s 10-Year ROE (%) Range
Min: -186.63   Max: 95.92
Current: -2.25

-186.63
95.92
ROA (%) -1.70
ELOS's ROA (%) is ranked higher than
66% of the 481 Companies
in the Global Medical Devices industry.

( Industry Median: 2.94 vs. ELOS: -1.70 )
ELOS' s 10-Year ROA (%) Range
Min: -120.76   Max: 48.19
Current: -1.7

-120.76
48.19
ROC (Joel Greenblatt) (%) -4.21
ELOS's ROC (Joel Greenblatt) (%) is ranked higher than
66% of the 480 Companies
in the Global Medical Devices industry.

( Industry Median: 9.33 vs. ELOS: -4.21 )
ELOS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -413.24   Max: 1713.63
Current: -4.21

-413.24
1713.63
Revenue Growth (3Y)(%) 2.40
ELOS's Revenue Growth (3Y)(%) is ranked higher than
82% of the 350 Companies
in the Global Medical Devices industry.

( Industry Median: 4.70 vs. ELOS: 2.40 )
ELOS' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 188.4
Current: 2.4

0
188.4
EPS Growth (3Y)(%) -54.00
ELOS's EPS Growth (3Y)(%) is ranked lower than
103% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: 2.70 vs. ELOS: -54.00 )
ELOS' s 10-Year EPS Growth (3Y)(%) Range
Min: -64   Max: 98.2
Current: -54

-64
98.2
» ELOS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

ELOS Guru Trades in Q2 2014

Charles Brandes 2,077,630 sh (+31.92%)
Seth Klarman 4,000,000 sh (unchged)
Mario Gabelli 24,000 sh (unchged)
Chuck Royce 987,059 sh (-5.74%)
Jim Simons 513,680 sh (-12.40%)
» More
Q3 2014

ELOS Guru Trades in Q3 2014

Steven Cohen 60,000 sh (New)
Charles Brandes 2,300,020 sh (+10.70%)
Mario Gabelli 24,000 sh (unchged)
Steven Cohen 66,500 sh (unchged)
Chuck Royce 987,059 sh (unchged)
Jim Simons 494,180 sh (-3.80%)
Seth Klarman 2,994,610 sh (-25.13%)
» More
Q4 2014

ELOS Guru Trades in Q4 2014

Jim Simons 534,967 sh (+8.25%)
Charles Brandes 2,338,530 sh (+1.67%)
Mario Gabelli 24,000 sh (unchged)
Steven Cohen Sold Out
Chuck Royce 881,759 sh (-10.67%)
Seth Klarman 2,416,310 sh (-19.31%)
» More
2015

ELOS Guru Trades in 2015

Seth Klarman 1,127,160 sh (-53.35%)
» More
» Details

Insider Trades

Latest Guru Trades with ELOS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 17.24
ELOS's Forward P/E is ranked higher than
91% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. ELOS: 17.24 )
N/A
P/B 1.89
ELOS's P/B is ranked higher than
83% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 4.25 vs. ELOS: 1.89 )
ELOS' s 10-Year P/B Range
Min: 0.58   Max: 10.23
Current: 1.89

0.58
10.23
P/S 1.68
ELOS's P/S is ranked higher than
79% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 3.71 vs. ELOS: 1.68 )
ELOS' s 10-Year P/S Range
Min: 1.08   Max: 15.69
Current: 1.68

1.08
15.69
PFCF 31.68
ELOS's PFCF is ranked higher than
51% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. ELOS: 31.68 )
ELOS' s 10-Year PFCF Range
Min: 4.32   Max: 1090
Current: 31.68

4.32
1090
POCF 26.64
ELOS's POCF is ranked higher than
70% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 75.76 vs. ELOS: 26.64 )
ELOS' s 10-Year POCF Range
Min: 4.15   Max: 541.5
Current: 26.64

4.15
541.5
EV-to-EBIT -154.87
ELOS's EV-to-EBIT is ranked higher than
69% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 75.34 vs. ELOS: -154.87 )
ELOS' s 10-Year EV-to-EBIT Range
Min: -327.8   Max: 1858.2
Current: -154.87

-327.8
1858.2
Current Ratio 2.94
ELOS's Current Ratio is ranked higher than
77% of the 473 Companies
in the Global Medical Devices industry.

( Industry Median: 2.48 vs. ELOS: 2.94 )
ELOS' s 10-Year Current Ratio Range
Min: 2.4   Max: 9.16
Current: 2.94

2.4
9.16
Quick Ratio 2.40
ELOS's Quick Ratio is ranked higher than
78% of the 473 Companies
in the Global Medical Devices industry.

( Industry Median: 1.88 vs. ELOS: 2.40 )
ELOS' s 10-Year Quick Ratio Range
Min: 2.26   Max: 8.89
Current: 2.4

2.26
8.89
Days Inventory 110.38
ELOS's Days Inventory is ranked higher than
82% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 165.69 vs. ELOS: 110.38 )
ELOS' s 10-Year Days Inventory Range
Min: 24.89   Max: 205.18
Current: 110.38

24.89
205.18
Days Sales Outstanding 79.78
ELOS's Days Sales Outstanding is ranked higher than
71% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 79.24 vs. ELOS: 79.78 )
ELOS' s 10-Year Days Sales Outstanding Range
Min: 50.5   Max: 120.06
Current: 79.78

50.5
120.06

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 2.38
ELOS's Price/Tangible Book is ranked higher than
86% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 7.75 vs. ELOS: 2.38 )
ELOS' s 10-Year Price/Tangible Book Range
Min: 0.71   Max: 9.33
Current: 2.38

0.71
9.33
Earnings Yield (Greenblatt) -0.60
ELOS's Earnings Yield (Greenblatt) is ranked higher than
64% of the 473 Companies
in the Global Medical Devices industry.

( Industry Median: 2.20 vs. ELOS: -0.60 )
ELOS' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 8327.2
Current: -0.6

0.1
8327.2

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:FGD.Germany,
Syneron Medical Ltd., was incorporated in the State of Israel in July 2000. The Company completed its initial public offering of ordinary shares in August 2004. It designs, develops and markets innovative aesthetic medical products based on its various technologies including its proprietary Electro-Optical Synergy, or ELOS, technology, which uses the synergy between electrical energy, including radiofrequency or RF energy, and optical energy to provide effective, safe and affordable aesthetic medical treatments. The Company's products, which it sells mainly to physicians and other practitioners, target non-invasive aesthetic medical procedures, including hair removal, wrinkle reduction, rejuvenation of the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, acne treatment, treatment of leg veins, treatment for the temporary reduction in the appearance of cellulite and thigh circumference, ablation and resurfacing of the skin and laser-assisted lipolysis and topical skin brightening products. ELOS provides performance advantages over existing technologies that rely solely on optical energy. The Company's proprietary ELOS technology, which combines optical and electrical energy, enhances the user's ability to accurately target the tissue to be treated and enables real-time measurement of skin temperature, resulting in increased patient safety and comfort and improved treatment results. As of March 1, 2014, its patent portfolio (including patents held by subsidiaries) consisted of 67 issued U.S. patents, and 96 patents applications pending in the U.S. (with an additional 370 applications pending internationally and 137 international patents), related to 114 patent families relating to its technology and products Its products compete against conventional non-light-based treatments, including Botox (neurotoxins) and hyaluronic acid injections, face lifts, sclerotherapy, electrolysis, liposuction, chemical peels and microdermabrasion. The Company's products are subject to extensive and rigorous regulation by the U.S. Food and Drug Administration, as well as other regulatory bodies.
» More Articles for ELOS

Headlines

Articles On GuruFocus.com
comment on ELOS Jan 31 2012 
note on ELOS Oct 08 2011 
Why Is Seth Klarman Loading Up on Syneron Medical? Aug 29 2011 
comment on ELOS Aug 20 2011 
comment on ELOS Aug 20 2011 
Seth Klarman’s Baupost Group Buys Microsoft Corp., BP, Allied Nevada Gold, Sells Audiovox Corp. Aug 12 2011 
Seth Klarman More Than Doubles Holdings in Syneron Medical Jul 12 2011 
Top Seth Klarman Holding, ELOS Rockets Up 20% Feb 17 2011 
Baupost’s Seth Klarman Buys Enzon Inc., Viasat Inc., Sells Horizon Lines Inc., News Corp., PDL Bio Nov 13 2009 
Magic Formula Moves, 4.23.08 Apr 23 2008 

More From Other Websites
Syneron Medical Ltd. Announces Availability of its Annual Report on Form 20-F through its Website Mar 25 2015
Syneron Medical Ltd. Announces Availability of its Annual Report on Form 20-F through its Website Mar 25 2015
Syneron Candela Presents Game-Changing Technologies During The American Academy of Dermatology... Mar 20 2015
Baupost Group Slightly Reduced Its Stake in Syneron Medical Mar 19 2015
Syneron Candela Launches "Changing Lives" Program At AAD Mar 17 2015
Syneron Candela Launches "Changing Lives" Program At AAD Mar 17 2015
Syneron Medical to Participate in the Barclays Global Healthcare Conference Mar 05 2015
Syneron Medical to Participate in the Barclays Global Healthcare Conference Mar 05 2015
Syneron Medical (ELOS) Enters Overbought Territory - Tale of the Tape Mar 03 2015
Coverage initiated on Syneron Medical by Brean Capital Mar 03 2015
Syneron Medical Reports Record Revenue of $74.1 Million for the Fourth Quarter 2014 Feb 18 2015
Syneron Medical reports 4Q loss Feb 18 2015
Syneron Medical reports 4Q loss Feb 18 2015
Q4 2014 Syneron Medical Ltd Earnings Release - Before Market Open Feb 18 2015
Syneron Candela's Ultrashape Is Challenging Exercise To Eliminate Stubborn Fat Feb 18 2015
Syneron Medical Reports Record Revenue of $74.1 Million for the Fourth Quarter 2014 Feb 18 2015
Syneron Candela's Ultrashape Is Challenging Exercise To Eliminate Stubborn Fat Feb 18 2015
Syneron Medical Appoints William Griffing to Newly Created Position of CEO of Syneron Candela North... Feb 12 2015
Syneron Medical to Report Fourth Quarter 2014 and Full Year 2014 Financial Results on February 18,... Feb 05 2015
Syneron Medical to Participate in the 2015 Leerink Global Healthcare Conference Feb 05 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK